Authors : I. B. Shelke; S. S. Wanjari; A. R. Jaiswal

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/yuyt352c

Scribd : https://tinyurl.com/mtvu23ra

DOI : https://doi.org/10.38124/ijisrt/26mar649

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Global Burden of Disease Study and other major global health - surveillance efforts show that parkinson’s disease (PD) has seen a sharp rise in prevelance over recent decades. In 1990, there were roughly 3.15 million people living with PD worldwide; by 2021, that number had increased to about 11.77 million - a rise of ~ 27.4%.The age - standardized prevalence rate increased from around 86 per 100,000 in 1990 to about 139 per 100,000 in 2021. According to 2019 estimates , over 8.5 million individuals globally had PD ; the disease burden - in terms of disability and mortality - also risen substantially. As of 2019, PD contributed to approximately 5.8 million disability adjusting life years and the number of ths attributed to PD was about 329,000 - reflecting more than 100% increase in PD- related deaths since 2000.Parkinson’s disease is one of the most common neurodegenerative disorders, affecting more than seven million people worldwide. It is primarily caused by the progressive degeneration of dopamine-producing neurons in specific regions of the brain, which results in a variety of motor symptoms such as tremor, rigidity, and slowed movement, along with several non-motor complications. The condition is complex and influenced by both genetic susceptibility and environmental factors that contribute to its development and prevalence in different populations. A key pathological feature of the disease is the formation of abnormal protein aggregates known as Lewy bodies within brain cells. Early diagnosis of Parkinson’s disease can be challenging because initial symptoms are often subtle and may appear years before the typical motor signs become evident. Effective management therefore requires improved diagnostic criteria, recognition of different disease subtypes, and the use of individualized treatment strategies to address the diverse clinical presentations and progression patterns of the disorder.

References :

1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, et al. 2000. Mice lacking α- synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239–252
2. Al-Chalabi A, Dürr A, Wood NW, Parkinson MH, Camuzat A, Hulot JS, Morrison KE, Renton A, Sussmuth SD, Landwehrmeyer BG, et al. 2009. Genetic variants of the α-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 4: e7114.
3. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K 2002. Tubulin seeds α-synuclein fibril formation. J Biol Chem 277: 2112–2117
4. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015 Aug 29;386(9996):896– 912. https://doi.org/10.1016/S0140-6736(14)61393-3. [PubMed]
5. Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996 May;14(2):317–35. https://doi.org/10.1016/S0733-8619(05)70259-0. [PMC free article] [PubMed]
6. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003 Apr 3;348(14):1356–64. https://doi.org/10.1056/NEJM2003ra020003. [PubMed]
7. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, et al. Identifying prodromal Parkinson’s disease: Pre-motor disorders in Parkinson’s disease. Mov Disord. 2012 Apr 15;27(5):617–26. https://doi.org/10.1002/mds.24996. [PubMed]
8. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997 Jun 27;276(5321):2045–7. https://doi.org/10.1126/science.276.5321.2045. [PubMed]
9. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. α-Synuclein locus triplication causes Parkinson’s disease. Science. 2003 Oct 31;302(5646):841. https://doi.org/10.1126/science.109027k8. [PubMed]
10. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov Disord. 2013 Jun;28(6):811–13. https://doi.org/10.1002/mds.25421. [PubMed]
11. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004 Feb;55(2):164–73. https://doi.org/10.1002/ana.10795. [PubMed]
12. Williams DR, Hadeed A, al-Din ASN, Wreikat A-L, Lees AJ. Kufor Rakeb disease: Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord. 2005 Oct;20(10):1264–71. https://doi.org/10.1002/mds.20511. [PubMed]
13. Lautier C, Goldwurm S, Dürr A, Giovannone B, Tsiaras WG, Pezzoli G, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 2008 Apr;82(4):822–33. https://doi.org/10.1016/j.ajhg.2008.01.015. [PMC free article] [PubMed]
14. Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet. 2005 Aug 1;14(15):2099–111. https://doi.org/10.1093/hmg/ddi215. [PubMed]
15. Wider C, Skipper L, Solida A, Brown L, Farrer M, Dickson D, et al. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat Disord. 2008 Aug;14(6):465–70. https://doi.org/10.1016/j.parkreldis.2007.11.013. [PubMed]
16. Greffard S, Verny M, Bonnet A-M, Beinis J-Y, Gallinari C, Meaume S, et al. Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol. 2006 Apr;63(4):584–8. https://doi.org/10.1001/archneur.63.4.584. [PubMed]
17. Cheng H-C, Ulane CM, Burke RE. Clinical progression in Parkinson’s disease and the neurobiology of axons. Ann Neurol. 2010 Jun;67(6):715–25. https://doi.org/10.1002/ana.21995. [PMC free article] [PubMed]
18. Rudow G, O’Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, et al. Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol. 2008 Feb 23;115(4):461. https://doi.org/10.1007/s00401-008-0352-8. [PMC free article] [PubMed]
19. Giguère N, Burke Nanni S, Trudeau L-E. On cell loss and selective vulnerability of neuronal populations in Parkinson’s disease. Front Neurol [Internet]. 2018 [cited 2018 Oct 18];9. Available from. https://www.frontiersin.org/articles/10.3389/fneur.2018.00455/full.